American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth

Journal of Surgical Oncology

Volumn 72, Issue 4, 1999, Pages 230-239

  Duda, Rosemary B ^a,c   Zhong, Ying ^a   Navas, Vinicio ^a   Li, Michael Z C ^b   Toy, Brian R ^b   Alavarez, Juan G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Chai Na Ta Corp   (Canada)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cell proliferation; Menopause; Phytoestrogens

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GINSENG EXTRACT; METHOTREXATE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; DRUG POTENTIATION; ESTROGEN ACTIVITY; GENE INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUGS, CHINESE HERBAL; FLOW CYTOMETRY; HUMANS; PACLITAXEL; PANAX; PLANTS, MEDICINAL; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0033461806     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199912)72:4<230::AID-JSO9>3.0.CO;2-2     Document Type: Article

References (44)

1. Downer SM, Cody MM, McCluskey P, et al.: Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. Br Med J 1994;309:86-89.
2. Arkko PF, Arkko BL, Kari-Koskinen O, et al.: A survey of unproven cancer remedies and their uses in an outpatient clinic for cancer therapy in Finland. Soc Sci Med 1980;14A:511-514.
3. Eisenberg DM, Kessler RC, Foster C, et al.: Unconventional medicine in the United States: Prevalence, costs, and patterns of use. N Engl J Med 1993;328:246-252.
4. Landes P: Survey indicates increasing herb use. American Botanical Council and Herb Research Foundation 'HerbalGram' 1996; 37:56.
5. Guzley GJ: Alternative cancer treatments: Impact of unorthodox therapy on the patient with cancer. South Med J 1992;85:519-523.
6. Verhoef MJ, Sutherland LR: Alternative medicine and general practitioners. Can Fam Phys 1995;41:1005-1011.
7. Ernst E, Resch KL, White AR: Complementary medicine: What physicians think of it - a meta-analysis. Arch Intern Med 1995; 155:2405-2048.
8. Spaulding-Albricht N: A review of some herbal and related products commonly used in cancer patients. J Am Diet Assoc 1997; (suppl 2):S208-S215.
9. Cassileth BR, Chapman CC: Alternative and complementary cancer therapies. Cancer 1996;77:1026-1034.
10. Begbie SD, Kerestes ZL, Bell DR: Patterns of alternative medicine use by cancer patients. Med J Aust 1996;165:5445-5448.
11. Dubick MA: Historical perspectives on the use of herbal preparations to promote health. J Nutr 1986;166:1348-1354.
12. Mindell E: "Herb Bible." New York: Fireside Publishers, 1991.
13. Minyi C: Anticancer Medicinal Herbs. Beijing, China: Hunan Science and Technology Press, 1992.
14. Liu CX, Xiao PG: Recent advances on ginseng research in China. J Ethnopharmacol 1992;36:27-38.
15. Hu SY: A contribution to our knowledge of ginseng. Am J Chin Med 1977;5:1-23.
16. Chang HM, But PPH: Renshen. In Chang HM, But PPH (eds): "Pharmacology and Applications of Chinese Materia Medica" (vol 1). Hong Kong: Chinese Medicinal Material Research Centre, The Chinese University of Hong Kong, World Scientific Publishers, 1982:17-31.
17. Yun TK, Choi SY: A case-control of ginseng intake and cancer. Int J Epidemiol 1990;19:871-876.
18. Chong SK, Oberholzer VG: Ginseng - Is there a use in clinical medicine? Postgrad Med J 1988;64:841-846.
19. Dean C: "Menopause naturally: A Wide Range of Natural Therapies to Help Women Through This Challenging Passage." Illinois: Keats Publishing, 1995.
20. Bachman GA: Nonhormonal alternatives for the management of early menopause in younger patients with breast cancer. J Natl Cancer Inst Monogr 1994;16:161-167.
21. Utian WH, Jacobwitz RS: "Managing Your Menopause." Upper Saddle River, NJ: Prentice Hall, 1990.
22. Horwitz KB, Zava DT, Thilagar AK, et al.: Steroid receptor analysis of nine human breast cancer cell lines. Cancer Res 1978;38: 2434-2437.
23. Westley B, May FEB, Brown AMC, et al.: Effects of anti-estrogens on the estrogen regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF7 cells and two tamoxifen resistant sublines. J Biol Chem 1984;259:10030-10035.
24. Feinberg AP, Vogelstein B: A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1984;137:266-267.
25. Ausubel FM, Brent R, Kingston RE, et al.: "Current Protocols in Molecular Biology." New York: John Wiley and Sons, 1989.
26. Camby I, Kiss R: In vitro estradiol-sensitivity characterization of the MCF-7, ZR-75, MDA-MB-231 and T-47D human breast neoplastic cell lines. Anticancer Res 1993;13:2355-2360.
27. Denizot F, Kang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89: 271-277.
28. Carmichael J, DeGraff WG, Gazdar AF, et al.: Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 1987;47:936-942.
29. Charlier C, Chariot A, Antoine N, et al.: Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells. Biochem Pharmacol 1995;49:351-358.
30. Labarea G, Paigen K: A simple, rapid and sensitive DNA assay procedure. Anal Biochem 1980;102:344-352.
31. WAFI/CIP1 via C/EBPbeta. Nature Med 1997;3:1233-1241.
32. Brunner N, Bronzert D, Vindelov LL, et al.: Effect of growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res 1989;49:1515-1520.
33. Setchell KD, Welsh MB, Lim CK: High-performance liquid chromatographic analysis of phytoestrogens in soy protein preparations with ultraviolet, electrochemical and thermospray mass spectrometric detection. J Chromatogr 1987;386:315-323.
34. Zava DT, Duwe G: Effects of plant (PE) and fungal (FE) estrogens (Es) on E-sensitive human breast cancer cells [abstract]. Proc Am Assoc Cancer Res 1994;35:A525.
35. Makela S, Poutanen M, Lehtimaki J, et al.: Estrogen-specific 17-beta-hydroxysteroid oxidoreductase type 1 (E.C.1.1.1.62.) as a possible target for the action of phytoestrogens. Proc Soc Exp Biol Med 1995;208:51-59.
36. Sathyamoorthy N, Wang TTY, Phang JM: Stimulation of pS2 expression by diet-derived compounds. Cancer Res 1994;54:957-961.
37. Kessel B, Duda RB, Prouty J, et al.: The use of antioxidants and unconventional alternatives to estrogen in postmenopausal women with and without breast cancer. Presented at the North American Menopause Society 5th annual meeting, 1994, abstract S-8.
38. Duda RB, Yang H, Kessel B, et al.: Ginseng induces the expression of the estrogen regulated gene pS2 in MCF-7 breast cancer cells. Ann Surg Oncol 1996;3:515-520.
39. Marchiori J, Alvarez J, Kessel B, et al.: Ginseng extract induces progesterone receptor in the estrogen responsive MCF-7 breast carcinoma cell line. Presented at the Society for Gynecologic Investigation 43rd annual meeting, 1996, abstract 101.
40. Planas-Silva MD, Weinberg RA: Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 1997; 17:4059-4069.
41. Pagliacci MC, Smacchia M, Migliorati G, et al.: Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer 1994;30A:1675-1682.
42. Petersen G, Barnes S: Genistein inhibits both estrogen and growth factor stimulated proliferation of human breast cancer cells. Cell Growth Differ 1994;7:1345-1351.
43. Wang TT, Sathyamoorthy N, Phang JM: Differential effects of genistein on pS2 expression and proliferation in MCF-7 cells are concentration dependent [abstract]. Proc Am Assoc Cancer Res 1994;35:A503.
44. Monti E, Sinha BK: Antiproliferative effect of genistein and Adriamycin against estrogen-dependent and -independent human breast cancer cell lines. Anticancer Res 1994;14:1221-1226.